When two worlds collide — big pharma meets big tech

network_data_pattern_collision_big

Yitzhak Peterburg, Teva Pharmaceutical Industries’ (NYSE: TEVA) last but one CEO, recently described the pharmaceutical industry as one of the last “traditional” industries, saying it was about to undergo “huge disruption.”

Dr Peterburg said that: "Part of our competitors are not only the Novartis of the world, and the other pharmas, but really the Amazons and Googles."

That claim might seem overblown, but as digital retailer Amazon weighs up becoming a pharmacist, and Californian behemoths Apple and Google invest vast sums in the healthcare space, it's clear that the pharmaceutical industry will in future do more and more business with, and to some degree compete with, Silicon Valley.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical